TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress

On June 13, 2017 (GLOBE NWarp* TG Therapeutics, Inc. (NASDAQ:TGTX), reported the schedule of presentations featuring TG-1101 and TGR-1202 at the upcoming 14th International Conference on Malignant Lymphoma (ICML), being held June 14 – 17, 2017, in Lugano, Switzerland and the upcoming 22nd European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress (EHA) (Free EHA Whitepaper), being held June 22 – 25, 2017, in Madrid, Spain (Press release, TG Therapeutics, JUN 13, 2017, View Source [SID1234519524]).

(Press release, TG Therapeutics, JUN 13, 2017, View Source [SID1234519524])

ICML PRESENTATION SCHEDULE:

Oral Presentations:

Title: Updated results of a multicenter phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CL
• Abstract Number: 040
• Presentation Date & Time: Wednesday, June 14, 2017 17:50 CEST
• Session Title: Chemotherapy-Free Combinations
• Presenter: Matthew S. Davids, MD, Dana-Farber Cancer Institute
Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
• Abstract Number: 101
• Presentation Date & Time: Friday, June 16, 2017 11:20 CEST
• Session Title: Session 7 – Advances in CLL
• Presenter: Anthony R. Mato, MD, University of Pennsylvania, Abramson Cancer Center
Title: Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
• Abstract Number: 102
• Presentation Date & Time: Friday, June 16, 2017 11:35 CEST
• Session Title: Session 7 – Advances in CLL
• Presenter: Loretta J. Nastoupil, MD, MD Anderson Cancer Center
Poster Presentation:

Title: Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma
• Abstract Number: 277
• Presentation Date: Friday, June 16, 2017 (Poster Session)
• Presenter: Mathew Lunning, DO, University of Nebraska, Omaha, NE
EHA PRESENTATION SCHEDULE:

Oral Presentation:

Title: Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
• Abstract Number: S772
• Presentation Date & Time: Sunday, June 25, 2017 8:45 – 9:00 CEST
• Session Title: Targeted therapies in relapsed chronic lymphocytic leukemia
• Location: Hall A
• Presenter: Loretta J. Nastoupil, MD, MD Anderson Cancer Center
Poster Presentation:

Title: Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma
• Abstract Number: P563
• Presentation Date & Time: Saturday, June 24, 2017 17:30 – 19:00 CEST
• Session Title: Aggressive Non-Hodgkin Lymphoma- Relapsed/Refractory
• Location: Poster Area Hall 7
• Presenter: Matthew Lunning, DO, University of Nebraska Medical Center
Abstracts are available online, respectively through the ICML meeting website at www.lymphcon.ch, or through the EHA (Free EHA Whitepaper) meeting website at www.ehaweb.org. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.